Bebifrin, drops 0.125% 10 ml

An anticonvulsant agent – alpha-adrenomimetic.

ATX code: R01AA04 Pharmacological properties

Pharmacodynamics

The drug for symptomatic local treatment of rhinitis. Phenylephrine hydrochloride is an agonist of alpha 1-adrenergic receptors (sympathomimetics) which produces vasoconstrictor effect due to stimulation of alpha1-receptors in the nasal mucosa, it reduces mucous membrane swelling and hyperemia of tissues, congestion in the nasal mucosa and improves nasal airway patency.

The restoration of nasopharyngeal airflow makes the patient feel better and reduces the risk of possible complications from mucociliary congestion.

Pharmacokinetics

In topical administration, systemic absorption is low.

Indications

Symptomatic treatment: to facilitate breathing through the nose in case of colds, flu, hay fever or other allergic diseases of the upper respiratory tract, accompanied by acute rhinitis or sinusitis.

Pharmacological effect

Anticongestant – alpha adrenergic agonist.

ATX code: R01AA04
Pharmacological properties

Pharmacodynamics

A drug for the symptomatic local treatment of rhinitis. Phenylephrine hydrochloride is an alpha1-adrenergic receptor agonist (sympathomimetics that have a vasoconstrictor effect due to stimulation of alpha1 receptors in the mucous membranes of the nasal cavity, reduces swelling of the mucous membranes and tissue hyperemia, congestion in the nasal mucosa, and also improves the patency of the nasal airways.

Restoring air patency of the nasopharynx improves the patient’s well-being and reduces the risk of possible complications caused by stagnation of mucous secretion.

Pharmacokinetics

When applied topically, systemic absorption is low.

Special instructions

Use in children

The use of the drug is contraindicated in children under 2 months of age. Use with caution in children under 6 years of age.

Active ingredient

Phenylephrine

Composition

1 ml of the drug contains:

Active ingredient:

Phenylephrine hydrochloride 1.25 mg

Excipients:

Benzalkonium chloride 0.18 mg

Glycerol anhydrous 50.00 mg

Macrogol 1500 (polyethylene glycol 1500) 15.00 mg

Sodium hydrogen phosphate dihydrate 2.26 mg

Potassium dihydrogen phosphate 1.01 mg

Disodium edetate dihydrate (trilon B) 0.20 mg

Water for injections up to 1 ml.

Pregnancy

There is no sufficient experience with the use of the drug during pregnancy.

It can be used for the treatment of pregnant and nursing mothers as prescribed by the attending physician, if the potential benefit to the mother outweighs the possible risk to the fetus or child.

Contraindications

increased individual sensitivity to the components of the drug;
severe uncontrolled arterial hypertension;
acute cardiovascular diseases;
tachyarrhythmia;
severe hyperthyroidism;
conditions after transsphenoidal hypophysectomy;
atrophic rhinitis;
simultaneous use of MAO inhibitors (as well as 2 weeks after their withdrawal);
inflammation of the skin and mucous membrane of the vestibule of the nose;
children up to 2 months.

With caution

Children’s age (up to 6 years); angle-closure glaucoma; diseases of the cardiovascular system (including coronary sclerosis, angina pectoris), arterial hypertension, diabetes mellitus, thyroid diseases. In such cases, it is recommended to consult a doctor.

Side Effects

Local reactions: burning sensation, tingling or tingling in the nose, irritation of the mucous membranes of the nasal cavity.

Systemic effects: headache, dizziness, palpitations, arrhythmia, increased blood pressure, sweating, pallor, tremor, sleep disturbance. Benzalkonium chloride, which is part of the drug, can cause irritation of the nasal mucosa.

Interaction

It is not recommended to use phenylephrine concomitantly with other decongestants (regardless of the route of administration) or with antihypertensive drugs.

MAO inhibitors (procarbazine, selegiline), tricyclic antidepressants, maprotiline, guanadrel, guanethidine enhance the vasoconstrictor effect and arrhythmogenicity of phenylephrine (with systemic absorption).

Concomitant use of phenylephrine simultaneously or within 14 days after treatment with MAO inhibitors may enhance the pressor effect.

Thyroid hormones during systemic absorption of phenylephrine mutually increase the associated risk of coronary insufficiency (especially in coronary atherosclerosis).

It is not recommended to use phenylephrine concomitantly with linezolid.

Overdose

There are no data on drug overdose.

Potentially possible symptoms (with systemic absorption): ventricular extrasystole, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, excessive increase in blood pressure, agitation, paranoia, hallucinations, nausea, vomiting.

Treatment: intravenous administration of short-acting alpha-blockers (phentolamine) and beta-blockers (for rhythm disturbances).

Storage conditions

Store at a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

Shelf life – 2 years. Do not use after the expiration date.
Shelf life after opening the bottle is 1 month.

Manufacturer

Grotex LLC, Russia